For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory. Commenting on the topline results, Professor Graham Finlayson, chair in psychobiology at the University of Leeds, said it was striking to see retatrutide reaching the weight loss range historically associated with bariatric surgery and that the headline efficacy results are impressive, particularly the proportion of participants reported to achieve very large weight losses. He added: In principle, that broader pharmacology could produce larger effects on body weight and metabolism, although the full peer-reviewed data will be needed to understand the balance between efficacy, tolerability and discontinuation. While this clinical trial did not examine weight regain after stopping retatrutide, other studies have found that discontinuing weight-loss medications such as semaglutide and liraglutide typically results in near-total weight regain within about 18 months

79 MasonH
With a portfolio of drugs that is likely to expand rapidly over the next few years, the Primary Care Diabetes & Obesity Society and its publications, including Diabetes & Primary Care and Diabetes Distilled , will help keep us all up to date.
And remember, more isnt more
The safety margin is over 300 times the therapeutic dose, making GHK-Cu one of the safest peptides available for research use
doi:10.1089/thy.2014.0028 174